15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $88M | -$785M | 0.0% | -695.4% | -$535M | $288M | $123M |
| 2024 | $18M | -$590M | 0.0% | -2902.7% | -$400M | $620M | $95M |
| 2023 | $8M | -$526M | 0.0% | -6589.7% | -$416M | $639M | $113M |
| 2022 | $95M | -$389M | 0.0% | -342.8% | -$311M | $650M | $66M |
| 2021 | $70M | -$215M | 0.0% | -264.5% | -$191M | $47M | $113M |
| 2020 | $56M | -$127M | 0.0% | -168.3% | -$2M | $46M | $83M |
| 2019 | $27M | -$122M | 0.0% | -368.0% | -$94M | $45M | $36M |
| 2018 | $32M | -$106M | 0.0% | -282.3% | -$102M | $42M | $42M |
| 2017 | $13M | -$128M | 0.0% | -848.3% | -$105M | $32M | $125M |
| 2016 | — | $16M | — | — | — | $30M | $67M |
| 2015 | — | -$38M | — | — | — | $15M | $65M |
| 2014 | — | -$15M | — | — | — | $0 | $20M |
| 2013 | — | -$34M | — | — | -$8M | — | $20M |
| 2013 | — | -$489M | — | — | -$402M | — | $19M |
| 2013 | — | -$477M | — | — | -$412M | — | $17M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $19M | -$206M | 0.0% | -948.7% | -$151M | $292M | $130M |
| Dec '25 | $18M | -$183M | 0.0% | -1004.6% | -$148M | $288M | $123M |
| Sep '25 | $2M | -$306M | 0.0% | -8613.4% | -$117M | $1.0B | $225M |
| Jun '25 | $67M | -$134M | 0.0% | -167.0% | -$132M | $610M | $75M |
| Mar '25 | $2M | -$161M | 0.0% | -9856.3% | -$137M | $610M | $74M |
| Dec '24 | $17M | -$150M | 0.0% | -821.4% | -$67M | $620M | $95M |
| Sep '24 | $463000 | -$161M | 0.0% | -30410.6% | -$102M | $620M | $47M |
| Jun '24 | $249000 | -$143M | 0.0% | -52277.9% | -$101M | $629M | $190M |
| Mar '24 | $835000 | -$136M | 0.0% | -15118.0% | -$130M | $630M | $120M |
| Dec '23 | $2M | -$137M | 0.0% | -7620.7% | -$74M | $639M | $113M |
| Sep '23 | $378000 | -$129M | 0.0% | -32345.2% | -$96M | $61M | $100M |
| Jun '23 | $867000 | -$129M | 0.0% | -14077.2% | -$123M | $62M | $69M |
| Mar '23 | $5M | -$131M | 0.0% | -2698.3% | -$123M | $64M | $102M |
| Dec '22 | $2M | -$137M | 0.0% | -6491.1% | -$101M | $650M | $66M |
| Sep '22 | $3M | -$142M | 0.0% | -4311.8% | -$90M | $64M | $106M |
| Jun '22 | $89M | -$20M | 0.0% | -12.2% | -$91M | $62M | $94M |
| Mar '22 | $1M | -$89M | 0.0% | -6782.0% | -$28M | $61M | $115M |
| Dec '21 | $56M | -$31M | 0.0% | -39.0% | -$62M | $47M | $113M |
| Sep '21 | $5M | -$76M | 0.0% | -1272.8% | -$54M | $47M | $91M |
| Jun '21 | $3M | -$62M | 0.0% | -1927.4% | -$38M | $47M | $37M |
How the market has priced CYTK against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cytokinetics Inc's revenue has grown 9.5% per year. These are computed facts, not advice.
As of FY2025, Cytokinetics Inc reported $288M of total debt against $123M of cash; operating income covered interest expense -13.4×.
In FY2025, gross margin was —, operating margin -695.4%, and net margin -891.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.